Powles, T., Choueiri, T. K., Motzer, R. J., Jonasch, E., Pal, S., Tannir, N. M., … George, D. J. (2021). Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer, 21(1), 1023. https://doi.org/10.1186/s12885-021-08693-9

Powles, Thomas, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, et al. “Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.” BMC Cancer 21, no. 1 (September 15, 2021): 1023. https://doi.org/10.1186/s12885-021-08693-9.

Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, et al. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Sep 15;21(1):1023.

Powles, Thomas, et al. “Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.” BMC Cancer, vol. 21, no. 1, Sept. 2021, p. 1023. Pubmed, doi:10.1186/s12885-021-08693-9.

Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Sep 15;21(1):1023.